FORMULATION AND EVALUATION OF GLICLAZIDE NANOSUSPENSION FOR SOLUBILITY AND DISSOLUTION ENHANCEMENT
DOI:
https://doi.org/10.22159/ajpcr.2025v18i11.55813Keywords:
BCS classification, Bioavailability, Dissolution, Nanosuspension, SolubilityAbstract
Objectives: The present aim of this research was to develop and characterize a gliclazide-containing nanosuspension using various polymers.
Methods: There are many approaches to enhance the low solubility and dissolution rate of medications and drug substances. A gliclazide nanosuspension with Soluplus, hydroxypropyl methylcellulose, and polyvinylpyrrolidone was formulated using the high-pressure homogenization method.
Results: The physiochemical properties of the drug, polymers, and evaluation characterization of nanosuspension were carried out using Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry, X-ray diffraction (XRD), viscosity, zeta potential, particle size, and solubility of nanosuspension were also checked. FTIR study explained that characteristic peaks of gliclazide were observed in all prepared batches. XRD study indicates that the crystalline structure of the drug was preserved in nanosuspension. The particle size of the formulation decreased using a nanosuspension.
Conclusion: Drug solubility was pH dependent, and the effect of nanosuspension on solubility was more pronounced at low pH values. Nanosuspension bioavailability is also influenced by the preparation of the nanosuspension. It was concluded that the nanosuspension method seems to be a promising technique for increasing the solubility, dissolution, and bioavailability of poorly water-soluble drugs.
Downloads
References
1. Aher SS, Malsane ST, Saudagar RB. Nanosuspension: An overview. Int J Curr Pharm Res. 2017;9(3):19-23. doi: 10.22159/ijcpr.2017.v9i3.19584
2. EL-Nabarawi M, Elsetouhy DA, Abdelmonem R, EL-Hosseini A. Enhancement of loratadine dissolution by surface solid dispersion: The potential use of co-processed excipients as on-surface carriers. Int J Appl Pharm. 2022;14(6):202-14.
3. Hanwate RM, Khairnar NS, Ramteke KH, Mundhe VS, Wasnik SP. Formulation and evaluation of nanosuspension for solubility and dissolution enhancement of poorly water-soluble drugs. Eur Chem Bull. 2022;11(12):5089-97.
4. Pawar AR, Chaudhary PD. Novel techniques for solubility, dissolution rate and bioavailability enhancement of class II and IV drugs. Asian J Biomed Sci. 2022;2:9-14.
5. Maio X, Sun C, Wang T, Jiang T, Zheng T, Wang S. Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol. J Pharm Pharm Sci. 2011;14:196-214.
6. Kimura K, Hirayama F, Arima H, Uekama K. Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-beta-cyclodextrin complex. Chem Pharm Bull (Tokyo). 2000;48(5):646-50. doi: 10.1248/cpb.48.646
7. Hanum TI, Prasetyo BE, Fadilla W. Formulation and in vitro tests of ketoprofen nanosuspension using the milling method with polymer variations. Int J Appl Pharm. 2024;16(6):57-63. doi: 10.22159/ ijap.2024v16i6.51843
8. Mandal B, Alexander KS, Riga AT. Sulfacetamide loaded eudragit® RL100 nanosuspension with potential for ocular delivery. J Pharm Pharm Sci. 2010;13:510-23.
9. Liu Y, Xie P, Zhang D, Zhang Q. A mini review of nanosuspensions development. J Drug Target. 2012;20(3):209-23. doi: 10.3109/1061186x.2011.645161, PMID 22192053
10. Sun W, Mao S, Shi Y, Li LC, Fang L. Nanonization of itraconazole by high pressure homogenization: Stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci. 2011;100(8):3365- 73. doi: 10.1002/jps.22587, PMID 21520089
11. Dekate S, Bhairy S, Hirlekar R. Preparation and characterization of oral nanosuspension loaded with curcumin. Int J Pharm Pharm Sci. 2018;10(6):90-5. doi: 10.22159/ijpps.2018v10i6.22027
12. Birade PA, Kilor VA. Formulation and evaluation of glimepiride nanosuspension using simple high shear homogenizer at lab scale. Int J Pharm Pharm Res. 2018;14(1):20-9.
13. El-Feky GS, Zayed G, Farrag AR. Optimization of an ocular nanosuspension formulation for acyclovir using factorial design. Int J Pharm Pharm Sci. 2013;15(1):213-9.
14. Chaudhari KP, Madhavi BL. Novel drug delivery technologies for insoluble drugs. Indian Drugs. 2005;42:557-63.
15. Aher SS, Malsane ST, Saudagar RB. Nanosuspension: An overview. Asian J Res Pharm Sci. 2017;7(2):81-6.
16. Nayak S, Panda D, Patnaik AK. Nanosuspension-preparation, in vitro and ex vivo evaluations of felodipine hydrochloride. Res J Pharm Tech. 2015;8(1):38-43. doi: 10.5958/0974-360x.2015.00008.6
17. Steffi PF, Shrinivasan M. Preparation, characterization and stabilization of curcumin nanosuspension. Int J Pharm Tech Res. 2014;6(2):842-9.
18. Mane AN, Gilda SS, Ghadge AA, Bhosle NR. Nanosuspension-a novel carrier for lipidic drug transfer. Sch Acad J Pharm. 2014;3(1):82-8.
19. Vasava SS, Chotai NP, Patel HK. Formulation and evaluation of nanosuspension drug delivery system of etoricoxib. Pharm Sci Monit. 2015;6(1):10-27.
20. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol. 2004;56(7):827-40. doi: 10.1211/0022357023691, PMID 15233860
21. Shilpa PC, Shrenik CK, Ritesh AM, Sachin J, Mukesh PR. Nanosuspension-a novel approaches in drug delivery system. Int J Pharm Res Rev. 2013;2:30-9.
22. Yadav M, Shashikant D, Prajakta C. Nanosuspension: Novel techniques in the drug delivery system. World J Pharm Sci. 2014;3:410-33.
23. Sunder VD, Divya P, Sridevi P, Akhila K, Dhanaraju MD. Design, formulation and evaluation of nanosuspension for drug delivery of celecoxib. Int J Pharmacol Res. 2019;11(1):139-45.
24. Reddy SM, Srigandh NN, Kumar CS. Gursale SC, Ragavan VV. In-vitro study of formulation and evaluation of nanosuspension of tamoxifen. Int J Basic Clin Pharmacol. 2018;7(5):926-34. doi: 10.18203/2319- 2003.ijbcp20181637
25. Gao L, Zhang D, Chen M, Zheng T, Wang S. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm. 2007;33(12):1332-9.
26. Gera S, Talluri S, Rangaraj N, Sampathi S. Formulation and evaluation of naringenin nanosuspensions for bioavailability enhancement. AAPS PharmSciTech. 2017;18(8):3151-62. doi: 10.1208/s12249-017-0790-5, PMID 28534300
27. Hanwate RM, Babu RH, Wadhave AA, Mishra V. Advancements in nanosuspension technology for drug delivery. Biomed Mater Devices. 2025;5(4):1-13. doi: 10.1007/s44174-025-00368-4
28. Liu G, Zhang D, Jiao Y, Zheng D, Liu Y, Duan C, et al. Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology. Int J Pharm. 2012;422:516-22.
29. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011;63(6):456-69.
30. Luo Y, Xu L, Tao X, Xu M, Feng J, Tang X. Preparation, characterization, stability and in vitro-in vivo evaluation of pellet-layered simvastatin nanosuspensions. Drug Dev Ind Pharm. 2013;39(7):936-46. doi: 10.3109/03639045.2012.699067, PMID 23046250
31. Liu P, Rong X, Laru J, Van Veen B, Kiesvaara J, Hirvonen J, et al. Nanosuspensions of poorly soluble drugs: Preparation and development by wet milling. Int J Pharm. 2011;411(1-2):215-22. doi: 10.1016/j. ijpharm.2011.03.050, PMID 21458552
32. Anjane M, Agrawal S, Khan A. Formulation and evaluation of nanosuspension of valsartan. Int J Curr Pharm Res. 2018;10(2):63-74.
33. Padmavati Y, Anjali A, Babu NR, Kumar PR. Development and validation of new FTIR method for quantitative analysis of gliclazide in bulk and pharmaceutical dosage form. Asian J Res Chem. 2017;10(3):377-82.
34. Jamadar SA, Muyle SP, Karekar PS, Pore YV, Burade KB. Development and validation of UV spectrophotometric method for the determination of gliclazide in tablet dosage form. Pharm Chem. 2011;3(4):338-43.
35. Firdos R, Anis S, Paul AK, Khan MS, Begum A, Kundu SK. In vitro release kinetic study of gliclazide from Methocel K100 MCR and Methocel K100 LVCR matrix tablet. Int J Pharm Technol Res. 2012;4(2):883-8.
Published
How to Cite
Issue
Section
Copyright (c) 2025 ravindra hanwate
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
